Production of Johnson & Johnson’s (JNJ.N) COVID-19 vaccine at a U.S.
manufacturing plant was halted by the U.S. Food and Drug Administration
while the agency investigates an error that led to millions of doses being
ruined last month.
Emergent BioSolutions Inc (EBS.N), the company that owns and runs the
Baltimore plant that had been making the J&J vaccine, said in a regulatory
filing that the FDA requested a pause on April 16 in production of new drug
substance for the shot pending completion of the inspection.
